Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:BLRX NASDAQ:CING NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.38+2.8%$1.98$0.95▼$2.87$21.37M0.13379,935 shs167,118 shsBLRXBioLineRx$4.68+1.7%$4.31$2.30▼$35.60$19.95M1.25234,122 shs10,451 shsCINGCingulate$4.71-0.2%$4.17$1.80▼$20.83$20.00M-0.791.10 million shs68,705 shsVIVSVivoSim Labs$1.87+3.3%$0.00$1.41▼$21.96$4.86M0.99422,811 shs66,191 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma+6.91%-1.69%+17.17%+128.57%-17.14%BLRXBioLineRx+1.77%-6.50%-1.50%+59.72%-85.91%CINGCingulate+4.42%+4.19%+4.66%+11.32%+1,276.49%VIVSVivoSim Labs-1.36%-4.49%+17.58%+180,999,900.00%+180,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYTUAytu BioPharma4.294 of 5 stars3.54.00.03.44.40.00.6BLRXBioLineRx2.6325 of 5 stars3.84.00.00.02.20.00.6CINGCingulate2.954 of 5 stars3.55.00.00.02.10.80.6VIVSVivoSim LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 3.00Buy$10.00319.46% UpsideBLRXBioLineRx 3.50Strong Buy$26.00455.56% UpsideCINGCingulate 3.00Buy$26.00452.02% UpsideVIVSVivoSim Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VIVS, CING, BLRX, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81M0.26N/AN/A$4.64 per share0.51BLRXBioLineRx$22.34M0.89N/AN/A$4.04 per share1.16CINGCingulateN/AN/AN/AN/A$2.32 per shareN/AVIVSVivoSim Labs$140K34.73N/AN/A$5.54 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/24/2025 (Estimated)BLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/21/2025 (Estimated)CINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)VIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,725.00%-46.87%-28.62%N/ALatest VIVS, CING, BLRX, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.030.87BLRXBioLineRx0.372.272.04CINGCingulate0.161.871.87VIVSVivoSim LabsN/A3.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%BLRXBioLineRx1.56%CINGCingulate41.31%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%BLRXBioLineRx1.10%CINGCingulate5.27%VIVSVivoSim Labs3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableBLRXBioLineRx404.26 million4.22 millionOptionableCINGCingulate204.25 million4.02 millionNot OptionableVIVSVivoSim Labs202.60 million2.50 millionN/AVIVS, CING, BLRX, and AYTU HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Datadog Joins S&P 500, Triggering a New Wave of UpsideBy Gabriel Osorio-Mazilli | July 7, 2025View Datadog Joins S&P 500, Triggering a New Wave of UpsideVIVS, CING, BLRX, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.38 +0.06 (+2.76%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.BioLineRx NASDAQ:BLRX$4.68 +0.08 (+1.74%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Cingulate NASDAQ:CING$4.71 -0.01 (-0.21%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.VivoSim Labs NASDAQ:VIVS$1.87 +0.06 (+3.31%) As of 02:02 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
